Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA).

"We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "At the same time, this product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form."

The Ciprodex® brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.

Dr. Reddy's Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle.

Ciprodex® is a trademark of Bayer AG.

Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.4692.55 as compared to the previous close of Rs. 4571.25. The total number of shares traded during the day was 46591 in over 4910 trades.

The stock hit an intraday high of Rs. 4754.3 and intraday low of 4601. The net turnover during the day was Rs. 218782698.

Source : Equity Bulls

Keywords